Pneumonia

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on: 
Tuesday, March 12, 2024
O'Hare International Airport, Miami International Airport, Genomics, Federation, Traveler, Pneumonia, JFK, Mycoplasma pneumoniae, Partnership, COVID-19, Public, DNA, Bacteria, MIA, SARS-CoV-2, RSV, Ginkgo Bioworks, Federal, Biosecurity, Mycoplasma, CDC, Airport, TGS, Collection, Vaccine

BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite pathogen screening, today announced they are expanding the CDC's Traveler-based Genomic Surveillance program (TGS) to new collection locations at US international airports in Miami (MIA) and Chicago (ORD).

Key Points: 
  • This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
  • In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
  • We are honored that CDC continues to trust this consortium to deliver a strategic piece of our biothreat preparedness."
  • "The additional funding of the program allows us to add infrastructure to support new mobile testing centers at Miami International Airport and Chicago O'Hare International Airport.

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
FDG, SAN, Research, Prostate cancer, Investment, Food, Pneumonia, CD19, Lymphoma, Therapy, CMR, Patient, Patient safety, Cytokine release syndrome, CRS, Pharmaceutical industry

Our grant revenue was $0.3 million for the fourth quarter ended December 31, 2023 and was $0.8 million for the full year 2023.

Key Points: 
  • Our grant revenue was $0.3 million for the fourth quarter ended December 31, 2023 and was $0.8 million for the full year 2023.
  • Our total operating expenses for the fourth quarter ended December 31, 2023 were $9.9 million, including $2.2 million in non-cash stock-based compensation expense.
  • Research and development expenses for the quarter totaled $6.7 million, and general and administrative expenses for the quarter totaled $3.3 million.
  • We believe these funds will be sufficient to fund our operations into the first quarter of 2025.

Antibiotic Drugs Market Analysis Report 2024: Surging Demand, Trends, and Forecasts 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024
Health, Pharmaceutical, Pfizer, Urinary tract infection, Merck, USD, GSK, Strategic planning, Cephalosporin, Pneumonia, Prevalence, Merck & Co., Meningitis, Infection, Pharmaceutical industry

The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.
  • The report meticulously evaluates the antibiotic drugs industry's landscape, emphasizing the key drug classes such as Cephalosporins, Penicillins, Macrolides, and Fluoroquinolones.
  • This investigation aligns with an increased emphasis on antibiotic stewardship and the urgent need for combating antibiotic resistance globally.
  • The Antibiotic Drugs Market report not only underscores the significant trends and growth drivers but also furnishes a detailed forecast, setting the stage for informed decision-making and strategic planning within the pharmaceutical sector.

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MRK, Research, CRL, New Drug Application, Investment, Eisai, Growth, Sale, Parent, Novin, Focal segmental glomerulosclerosis, Streptococcus, LGND, FSGS, Breakthrough therapy, BLA, AED, GAAP, Therapy, NASH, Liver, NDA, Depreciation, Breast cancer, Total, Forecasting, Perampanel, Shanda, Telecanthus, ID, Retirement, PDUFA, Vaccine, Symantec Endpoint Protection, Type 2 diabetes, Safety, VRNA, Molluscum contagiosum, F2, Acquisition, Caregiver, Merck, AASLD, FDA, Telephone, Food, Pneumonia, Income tax, Hepatology, COVID-19, Element, Patient, SPA, Pharmaceutical industry

Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.

Key Points: 
  • Royalties for the fourth quarter of 2023 were $22.5 million, compared with $22.0 million for the same period in 2022.
  • Costs of Captisol sales were $1.6 million for the fourth quarter of 2023, compared with $21.6 million for the same period in 2022, with the decrease due to lower total Captisol sales during the fourth quarter of 2023 and $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the fourth quarter of 2022.
  • Amortization of intangibles was $8.3 million for the fourth quarter of 2023, compared with $8.5 million for the same period in 2022.
  • Travere also announced fourth quarter 2023 results reporting that it received 459 new patient start forms for FILSPARI in the fourth quarter of 2023 and net product sales of $14.9 million for the fourth quarter.

American, Finnish and Canadian governments fund oxygen plant at Tatu City SEZ, Kenya

Retrieved on: 
Wednesday, March 6, 2024
Oxygen, George Soros, Davis & Shirtliff, Woman, Ministry, Student, Transport, Pneumonia, Grand Challenges Canada, Pregnancy, Heineken, Ministry of Health, Organization, COVID, CCI, Child, DFC, Mortality, Pharmaceutical industry

TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City Special Economic Zone (SEZ), the 5,000-acre new city on Nairobi's doorstep.

Key Points: 
  • TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City Special Economic Zone (SEZ), the 5,000-acre new city on Nairobi's doorstep.
  • Hewatele will use the debt and equity funds raised to finance the building of a cutting-edge Cryogenic Medical Liquid Oxygen Air Separation Unit plant at Tatu Industrial Park.
  • Dr Bernard Olayo, Founder of Hewatele, said: "This medical oxygen plant represents a significant leap in ensuring sustainable and affordable access to medicinal oxygen.
  • The increased production capacity here at Tatu City will improve oxygen affordability, particularly for maternal and child healthcare, and enhance primary healthcare support."

American, Finnish and Canadian governments fund oxygen plant at Tatu City SEZ, Kenya

Retrieved on: 
Wednesday, March 6, 2024
Oxygen, George Soros, Davis & Shirtliff, Woman, Ministry, Student, Transport, Pneumonia, Grand Challenges Canada, Pregnancy, Heineken, Ministry of Health, Organization, COVID, CCI, Child, DFC, Mortality, Pharmaceutical industry

TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City Special Economic Zone (SEZ), the 5,000-acre new city on Nairobi's doorstep.

Key Points: 
  • TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City Special Economic Zone (SEZ), the 5,000-acre new city on Nairobi's doorstep.
  • Hewatele will use the debt and equity funds raised to finance the building of a cutting-edge Cryogenic Medical Liquid Oxygen Air Separation Unit plant at Tatu Industrial Park.
  • Dr Bernard Olayo, Founder of Hewatele, said: "This medical oxygen plant represents a significant leap in ensuring sustainable and affordable access to medicinal oxygen.
  • The increased production capacity here at Tatu City will improve oxygen affordability, particularly for maternal and child healthcare, and enhance primary healthcare support."

Experts Urge Vaccination as Measles Cases Rise

Retrieved on: 
Tuesday, March 5, 2024
Infection, NFID, RN, News, Pneumonia, Immunodeficiency, Vaccination, Vaccine, Vitamin A, Death, Brain damage, MPH, MMR, Disease, Immunity, CPNP, Measles vaccine, Seizure, Public

With measles cases on the rise, experts are urging everyone to make sure they are up to date on vaccination.

Key Points: 
  • With measles cases on the rise, experts are urging everyone to make sure they are up to date on vaccination.
  • Measles was declared eliminated in the US in 2000, but cases still occur when international travelers who get measles overseas bring it into the US or as cases spread in US communities with pockets of unvaccinated people.
  • Severe measles cases among children, including those who are hospitalized, may be treated with vitamin A, according to an NFID report on Vitamin A for the Management of Measles in the US .
  • NFID experts are available to talk about measles, the recent increase in cases in the US, the importance of measles vaccination as recommended, and treatment with vitamin A for severe cases.

SENA Health Announces Partnership with Inspira Health to Support Hospital-Level Care in the Home

Retrieved on: 
Tuesday, March 5, 2024
Urinary tract infection, Hospital, Physician, HOME, Health, United States Senate, Asthma, ED, Cellulitis, Pneumonia, Vital signs, CHF, Chronic obstructive pulmonary disease, Heart failure, Home, Observation, Medicare, Patient, UTI, Senate, COPD, Partnership

PHILADELPHIA, March 5, 2024 /PRNewswire/ -- SENA Health announces its partnership with Inspira Health to support patients receiving Healing at Home clinical services. The home-based services deliver advanced-level care to eligible Inspira Health patients in the comfort of their own homes. The program combines expert care with advanced technology to offer a seamless, integrated service that maximizes health outcomes.

Key Points: 
  • PHILADELPHIA, March 5, 2024 /PRNewswire/ -- SENA Health announces its partnership with Inspira Health to support patients receiving Healing at Home clinical services.
  • The home-based services deliver advanced-level care to eligible Inspira Health patients in the comfort of their own homes.
  • "Inspira Health sets itself apart as a truly innovative and forward-thinking organization in the region," said Dr. Anthony Wehbe, Founder and CEO of SENA Health.
  • Inspira Health, in collaboration with SENA, has recently obtained the CMS Acute Hospital Care at Home Waiver.

Breathe Change: Lung Health Foundation Launches First of Three Landmark Policy Forums on Thursday, March 7

Retrieved on: 
Monday, March 4, 2024
Chairperson, Clinical Practice, RSV, Education, Building, Spirometry, Hospital, Overalls, Asthma, Pneumonia, Assembly, Hope, LHF, Long-term care, Climate change, Patient, Policy, Health policy, Lung cancer, Health professional, Diagnosis, Wildfire, Mortality, Public, Research, Radon, Health insurance

LHF is the nation's leading non-profit organization dedicated to supporting and empowering individuals living with lung conditions across Canada.

Key Points: 
  • LHF is the nation's leading non-profit organization dedicated to supporting and empowering individuals living with lung conditions across Canada.
  • The session showcases the best-of-the-best in COPD and lung disease research, diagnosis and treatment modalities, and policy initiatives.
  • Dawn Bowdish, Executive Director, Firestone Institute for Respiratory Health and Dr. Maya de Zoysa, Respirologist, West Nipissing General Hospital.
  • For those navigating the labyrinth of lung disease, LHF offers an expansive array of disease-specific support programs and resources.

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management

Retrieved on: 
Monday, March 4, 2024
Aphelion, Sector, FDA, ISC, EQT, Dysphagia, Pneumonia, Stroke, Entrepreneurship, Risk, Conference, Health Economics, Saliva, Patient, Brain, Patient capital, Economics, Mortality, Research, Pharmaceutical industry

The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.

Key Points: 
  • The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.
  • Patients with swallowing dysfunction (dysphagia) are unable to safely or effectively eat, drink, or manage their own saliva.
  • Dysphagia can often lead to life threatening complications such as pneumonia and is also associated with substantially higher healthcare costs.
  • Drew Burdon, Partner at EQT Life Sciences, said: "Dysphagia is a severe medical condition that affects countless patients in hospital.